SFDA CEO Pushes for Massive Biotech Partnerships with Korean Companies

Securing Advanced Medical Tech

Saudi Arabia is aggressively expanding its footprint in the global medical sector. Saudi Food and Drug Authority (SFDA) CEO Dr. Hisham Aljadhey held high-level roundtable talks in Seoul today. He met directly with leading Korean private-sector executives to discuss immediate cooperation in biotechnology and advanced therapies. The meeting took place alongside the International Coalition of Medicines Regulatory Authorities (ICMRA) Summit. Saudi Arabia’s Commercial Attaché Saeed Almadani also attended the strategic discussions to help lock in future partnerships.

Fast-Tracking Rare Disease Cures

The SFDA refuses to let bureaucracy slow down medical progress. Dr. Aljadhey highlighted the "NADR" regulatory pathway designed to rapidly accelerate the introduction of crucial medicines for rare diseases. The authority is overhauling its regulatory framework to keep pace with cutting-edge scientific developments. They want to expedite the registration of advanced treatments without compromising strict quality and safety standards. Saudi Arabia demands immediate patient access to the best innovative treatments available globally.

Building a Global Hub

The National Biotechnology Strategy aims to transform the Kingdom into a leading global medical hub under Vision 2030. Dr. Aljadhey toured a specialized Korean research facility focusing on groundbreaking CAR T-cell therapy. The SFDA wants to leverage the Riyadh Biocentral Foundation to integrate Saudi research entities with specialized international centers. These strategic discussions ensure Korean tech companies understand Saudi regulatory pathways, opening the door for massive medical investments in the Kingdom.

Track the medical breakthroughs shaping the Kingdom. Get the latest healthcare news on Marhaba Saudi.